Search for: [Abstract = "Material and methods\: The analysis included Polish and international expert guidelines for the treatment of diseases from the spectrum of eczema that were published within the last ten years. These recommendations were confronted with SPC of recommended drugs in order to select those which were officially licensed for the treatment of a given type of eczema. A systematic review of clinical trials of recommended or registered drugs was carried out with the quality of published results assessed according to the GRADE scale. Attention was paid to the discrepancies between expert recommendations and official indications as determined in the SPC. An additional analysis was done of regulations concerning reimbursement of drugs recommended or registered for the treatment of diseases from the spectrum of eczema. Results\: The analysis included 20 recommendations by experts bodies, 565 SPC, 90 published results of clinical trials of drugs both recommended by expert bodies and registered in Poland for treating diseases from the spectrum of eczema, results of 85 trials of drugs that were recommended by experts, but not licensed in Poland for the treatment of eczema, as well as 3 trial results of drugs that were not recommended by experts, yet still licensed in Poland for treating certain types of eczema. From the list of drugs recommended by expert bodies for the treatment of atopic eczema \(AE\), 387 medicinal products containing altogether 38 pharmacological substances, as well as 20 emollients and 77 vaccines for allergen\-specific immunotherapy were licensed for the use in Poland. Among theme, there were 84 medicinal products containing 25 active substances, and 5 emollients with official indication for the treatment of AE. Among the medicinal products both recommended by expert bodies and registered in Poland for the treatment of AE, clinical trials of high\- or moderate quality have confirmed the efficacy of active components of 36 medicinal products, including 2 topical calcineurin inhibitors \(pimecrolimus – 3 products, tacrolimus – 2 products\), oral ciclosporin \(12 medicinal products\), and 19 out of 45 topical"]
